EP Patent

EP0205247B1 — Derivatives of quinuclidine

Assigned to STATE OF ISRAEL REPRESENTED BY PRIME MINISTER'S OFFICE ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH · Expires 1992-12-16 · 33y expired

What this patent protects

Quinuclidine derivatives having the general formula (I) <IMAGE> and geometrical isomers, enantiomers, diastereoisomers, racemates and/or acid addition salts thereof, wherein Z represents the group >CR1R2 or two hydrogen atoms; and R1 and R2, which may be identical or d…

USPTO Abstract

Quinuclidine derivatives having the general formula (I) <IMAGE> and geometrical isomers, enantiomers, diastereoisomers, racemates and/or acid addition salts thereof, wherein Z represents the group >CR1R2 or two hydrogen atoms; and R1 and R2, which may be identical or different, are each alkyl, cyclopentyl, cyclohexyl, aryl, or diarylmethylol, or alkyl which is substituted by one or more aryl groups, or one of R1 and R2 may be hydrogen.

Drugs covered by this patent

Patent Metadata

Patent number
EP0205247B1
Jurisdiction
EP
Classification
Expires
1992-12-16
Drug substance claim
No
Drug product claim
No
Assignee
STATE OF ISRAEL REPRESENTED BY PRIME MINISTER'S OFFICE ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.